Classical Hematology

In previously sedentary young males and females, 14 days of moderate aerobic exercise increased red and white blood cell counts and hemoglobin concentrations without altering key cardiometabolic enzymes.

Older age and being insured with Medicare or Medicaid were associated with heightened annual joint bleeding rates, whereas treatment in the Northeast United States improved outcomes in both hemophilia A and hemophilia B.

Ononogbu discusses research, health equity, and sickle cell advancements.

Pharmacists can optimize management of this condition with intravenous iron therapy guidance.

The patient is the first to be cured using lovotibeglogene autotemcel, a novel cell-based gene therapy.

Compared with daily oral iron, a single intravenous (IV) infusion of iron was shown to lower rates of low birth weight in infants and decrease reliance on further iron supplementation or transfusions in pregnant patients with anemia.

Following allogeneic hematopoietic stem cell transplantation (allo-HSCT), luspatercept effectively improved signs of anemia in patients with a variety of hematologic conditions.

The new data demonstrates the effectiveness of Mim8 in children with hemophilia A regardless of inhibitor status, expanding the populations in which the novel drug in development could have a treatment benefit.

Improvements in baseline for markers of hemolysis (indirect bilirubin, lactate dehydrogenase, and haptoglobin) were observed only in the mitapivat arm.

Prescribing and dosing appropriate treatments for patients with sickle cell disease while managing episodes of acute pain are some of the integral roles of pharmacists.

A one-time infusion of etranacogene dezaparvovec-drlb led to sustained bleeding control and a reduction in factor IX prophylaxis in patients with hemophilia B.

Thalassemia, a chronic blood condition that reduces hemoglobin levels, requires a hands-on approach from pharmacists in patient monitoring and diagnosis.

Higher p16 expression in patients with sickle cell disease led to heightened risk of age-related complications.

Fitusiran is part of a generation of novel RNA interference therapies and is designed for subcutaneous administration for the prophylactic treatment of hemophilia A or B.

Pharmacists can improve hyperkalemia management through collaboration and innovation.

Abelacimab (Anthos Therapeutics Inc) is a novel factor XI inhibitor being investigated for the reduction of bleeding for patients with atrial fibrillation.

Multiple treatments have been approved by regulators for the treatment of hemophilia A and B, giving pharmacists options for their patients.

These drugs are set to revolutionize their respective disease states in 2025.

High-cost medications necessary for treatment require close management to ensure patient safety and to adhere to payer-specific requirements.

Data from a follow-up at 6 months show a reduced risk of all-cause mortality in heart attack patients with anemia who receive a liberal transfusion strategy compared with a restrictive one.

Pharmacists should be aware of the impacts that anemia in patients being treated for cancer has on daily activities and overall quality of life.

Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.

Concizumab-mtci is a subcutaneous, monoclonal antibody designed to achieve hemostasis in all hemophilia types.

Anemia is a common adverse effect of ruxolitinib, calling for new approaches to mitigate risks.

Clinical trial analysis results studying VAD-44 in patients with hereditary hemorrhagic telangiectasia (HTT) will be presented at the 2024 American Society of Hematology Annual Meeting & Exposition.

Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen.

By utilizing a lower dose, patients can avoid potential adverse events and high financial burden.

Eculizumab (Soliris; Alexion), a C5 inhibitor preventing cleavage into C5a and C5b, is widely considered the first-line therapy for high-risk TA-TMA.